$0.55
Value $58M
HYPR and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$0.55
Value $58M
$270.47
Value $652B
Hyperfine (HYPR) has a market value of $58M and Johnson & Johnson (JNJ) $652B. Over the last year, with dividends, HYPR moved -48.9% and JNJ +36.6%. Dividend yield: HYPR none, JNJ 1.95%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
HYPR$58M
JNJ$652B
JNJ is 11,240 times HYPR
Revenue, 12 months
HYPR$19M
JNJ$99.3B
JNJ is 5,212 times HYPR
Net income, 12 months
HYPR-$30M
JNJ$16.1B
Operating margin
HYPR-167.6%
JNJ–
ROIC
HYPR-59.9%
JNJ12.4%
72.3 points apart
P/E
HYPR–
JNJ40.5
Dividend yield
HYPR0.0%
JNJ2.0%
2.0 points apart
5-year return
HYPR-94.5%
JNJ+90.9%
185.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
HYPR-94.5%
JNJ+90.9%
| Period | HYPRWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | -48.9%Price -48.9% | +36.6%Price +33.6% |
| 3 years since November 20, 2023 | -53.2%-22.4% a yearPrice -53.2% | +94.9%+24.9% a yearPrice +80.4% |
| 5 years since November 19, 2021 | -94.5%-44.0% a yearPrice -94.5% | +90.9%+13.8% a yearPrice +66.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
HYPRHyperfineJNJJohnson & Johnson
| Price | $0.55 | $270.47 |
|---|---|---|
| Market value | $58M | $652B |
| Enterprise value (EV) | $33M | $679B |
| P/E | – | 40.5 |
| P/E, 5-year median | – | 21.9 |
| P/B | 1.8 | 8.0 |
| EV/EBIT | – | 38.3 |
| Free cash flow yield | – | 3.2% |
| Revenue, 12 months | $19M | $99.3B |
|---|---|---|
| Net income, 12 months | -$30M | $16.1B |
| Free cash flow, 12 months | -$28M | $20.6B |
| Earnings per share, 12 months | -$0.29 | $6.59 |
| Revenue growth, year on year | 5.2% | 6.1% |
| Revenue growth a year, past | +115.2%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | 52.7% | 67.6% |
|---|---|---|
| Operating margin | -167.6% | – |
| Net margin | -156.4% | 16.2% |
| ROIC | -59.9% | 12.4% |
| ROE | -87.3% | 19.7% |
| Cash | $38M | $17.2B |
|---|---|---|
| Total debt | $14M | $44.7B |
| Net debt / EBITDA | – | 1.1 |
| Interest cover | – | 18.0× |
| Dividend yield | – | 2.0% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | – | 0.9% |
| Shareholder yield | – | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($652B) is about 11,240.1 times Hyperfine ($58M), at today's prices.
Since November 19, 2021, HYPR's price moved -94.5% and JNJ's +66.0%. With dividends: HYPR -94.5% (-44.0% a year), JNJ +90.9% (+13.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Hyperfine and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
Over the last twelve months, the net margin was -156.4% for Hyperfine and 16.2% for Johnson & Johnson, and the operating margin -167.6% and –. Revenue was $19M and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.